Regorafenib
Nov. 4, 2024
Stivarga (Regorafenib) for Treating Metastatic Colorectal Cancer (mCRC) - Clinical Trials Arena Regorafenib | C21H15ClF4N4O3 | CID 11167602 - PubChem Regorafenib, multikinase inhibitor (CAS 755037-03-7) (ab216314) | Abcam Bayer's Stivarga® (regorafenib) Tablets Approved by U.S. FDA for Treatment of Patients with Locally Advanced, Unresectable or Metastatic GIST | Regorafenib